Akari Therapeutics PLC (AKTX) — 10-Q Filings

10-Q Filings (6)

• Akari Narrows Loss to $12M, But Intangible Impairment Hits Q3 — Nov 13, 2025 Risk: high
  Akari Therapeutics Plc reported a net loss of $12.0 million for the nine months ended September 30, 2025, a significant improvement from the $16.0 million net l
• Akari Narrows Losses, Shifts Focus to ADC Platform Post-Peak Bio Merger — Aug 13, 2025 Risk: high
  Akari Therapeutics Plc (AKTX) reported a net loss of $5.6 million for the six months ended June 30, 2025, a significant improvement from the $13.124 million net
• Akari Therapeutics Plc Files 10-Q for Q1 2025 — May 14, 2025 Risk: medium
  Akari Therapeutics Plc filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals P
• Akari Therapeutics Plc Files Q3 2024 10-Q — Nov 19, 2024 Risk: medium
  Akari Therapeutics Plc filed a 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial da
• Akari Therapeutics Files Q2 2024 10-Q — Aug 19, 2024 Risk: medium
  Akari Therapeutics Plc filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and business operations, including det
• Akari Therapeutics Plc Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  Akari Therapeutics Plc (AKTX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Akari Therapeutics Plc filed a 10-Q report for the period ending Mar

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX